Condition: Melanoma · Non Small Cell Lung Cancer · Solid Tumor · Sponsor: Novartis Pharmaceuticals
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Honor Health Research Institute | Scottsdale, Arizona, United States | Active Not Recruiting |
| National Institute Of Health | Bethesda, Maryland, United States | Active Not Recruiting |
| James Cancer Hospital and Solove Research Institute Ohio State | Columbus, Ohio, United States | Completed |
| Mary Crowley Cancer Research | Dallas, Texas, United States | Completed |
| Novartis Investigative Site | Caba, Buenos Aires, Argentina | Completed |
| Novartis Investigative Site | Innsbruck, Tyrol, Austria | Active Not Recruiting |
| Novartis Investigative Site | Beijing, China | Completed |
| Novartis Investigative Site | Copenhagen, Denmark | Active Not Recruiting |
| Novartis Investigative Site | Lyon, France | Active Not Recruiting |
| Novartis Investigative Site | Nantes, France | Active Not Recruiting |
| Novartis Investigative Site | Paris, France | Recruiting |
| Novartis Investigative Site | Paris, France | Completed |
+ 20 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03340506